{"entity":{"id":"nct06464055","kind":"trial","name":"A Study of GQ1010 in Subjects With Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of Dose Escalation in advanced solid tumours, run by GeneQuantum Healthcare (Suzhou) Co., Ltd., now recruiting.","summary":"A Study of GQ1010 in Subjects With Advanced Solid Tumors. ClinicalTrials.gov record last updated 2025-02-10: recruiting. Enrollment is planned at 260 participants. Primary completion is estimated at 2028-05-23. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications. Registered interventions: Dose Escalation, Dose Expansion1, Dose Expansion2, Dose Expansion3, phase II. Registered primary measures: Phase I/II: Incidence and Severity of Adverse Events (AEs); Phase Ia: Dose Limiting Toxicities (DLTs); Phase Ia: Maximal Tolerance Dose (MTD) or recommended doses for dose expansion (RDEs).","status":"recruiting","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT06464055","url":"https://clinicaltrials.gov/study/NCT06464055"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":["adc"],"targets":["trop2"],"drugs":[],"companies":["genequantum-healthcare-suzhou"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["ClinicalTrials.gov record last updated 2025-02-10: recruiting. Enrollment is planned at 260 participants. Primary completion is estimated at 2028-05-23. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications."],"nct":"NCT06464055","phase":"1/2","setting":"A Study of GQ1010 in Subjects With Advanced Solid Tumors","sponsor":"GeneQuantum Healthcare (Suzhou) Co., Ltd.","participation":[{"nct":"NCT06464055","source":"https://clinicaltrials.gov/study/NCT06464055","fetchedAt":"2026-10-07T16:54:41.796Z","studySha256":"3400239954b4519eafd2f2efbbe4721fc2a3a4603ae1988af10fe8ad650ec741","overallStatus":"RECRUITING","lastUpdatePosted":"2025-02-10","leadSponsor":"GeneQuantum Healthcare (Suzhou) Co., Ltd.","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":260,"enrolmentType":"ESTIMATED","siteCount":5,"recruitingSiteCount":5,"countries":["China"]}],"started":"2024-05-23","startedType":"actual","enrolled":260,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06464055/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"target":[{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/"}],"company":[{"id":"genequantum-healthcare-suzhou","kind":"company","name":"GeneQuantum Healthcare (Suzhou)","route":"/companies/genequantum-healthcare-suzhou/"}],"drug":[{"id":"bhv-1510","kind":"drug","name":"BHV-1510","route":"/drugs/bhv-1510/"}]}}